Javelin Pharmaceuticals
125 CambridgePark Drive
Cambridge
Massachusetts
02140
United States
Tel: 617-349-4500
Fax: 617-349-4505
142 articles about Javelin Pharmaceuticals
-
Javelin Pharmaceuticals Announces Successful Completion of Tender Offer for Shares of Hospira, Inc.
7/1/2010
-
Hospira, Inc. Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
6/29/2010
-
News Release Service Inadvertently Issues Hoax Press Release Identifying Javelin Pharmaceuticals as Issuer
6/21/2010
-
Hospira, Inc. Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
6/17/2010
-
Javelin Pharmaceuticals Receives $2 Million Loan from Hospira, Inc.
6/11/2010
-
Javelin Pharmaceuticals Receives Notice From NYSE Amex LLC of Non-Compliance
6/7/2010
-
Javelin Pharmaceuticals Receives Notice from Hospira, Inc. of Funding of Loan
6/7/2010
-
Javelin Pharmaceuticals Sues Hospira, Inc. Alleging Breach of Merger Deal
6/3/2010
-
Javelin Pharmaceuticals Says Pain Drug to be Withdrawn from UK Market Due to Quality Control Problems
5/24/2010
-
Javelin Pharmaceuticals Comments on Tender Offer Extension by Hospira, Inc.
5/19/2010
-
Hospira, Inc. Announces Extension of Tender Offer for Shares of Javelin Pharmaceuticals
5/19/2010
-
Javelin Pharmaceuticals Reports First Quarter 2010 Results
5/11/2010
-
Javelin Pharmaceuticals Announces Termination of Merger Agreement with Myriad Pharmaceuticals, Inc., Cancels Special Meeting of Stockholders
4/19/2010
-
Hospira, Inc. and Javelin Pharmaceuticals Enter Into Definitive Merger Agreement for Hospira to Acquire Javelin for Approximately $145 Million
4/19/2010
-
Myriad Pharmaceuticals, Inc. Receives Notice of Javelin Pharmaceuticals's Intent to Terminate Merger Agreement
4/12/2010
-
Myriad Pharmaceuticals, Inc. Sets Date for Special Stockholder Meeting to Approve Merger with Javelin Pharmaceuticals
3/15/2010
-
Javelin Pharmaceuticals Reports Fiscal Results for the Year Ended 2009
3/9/2010
-
New Hope For Javelin Pharmaceuticals's Pain Candidate But Safety Concerns Remain
2/26/2010
-
Javelin Pharmaceuticals' Receives FDA PDUFA Date for Dyloject NDA
2/17/2010
-
Third Party Reexamination of Javelin Pharmaceuticals' Phase III Trial Data for Ereska (Intranasal Ketamine) Yields Statistically Significant Primary Endpoint
2/11/2010